Sams epharmacy cum Pharmaclinic cum DIC cum PVC
This site is made to provide information about recently started Pharm D and Pharm D(Post Bacclaurreatte) courses in india to all
Monday, 7 September 2026
Alternative Medicine
Sunday, 30 August 2026
Collaborative Practice Agreement (Clinical) (CPA)
- What it is: A formal, legally binding document between a pharmacist and a physician (or other healthcare provider).
- Function: It grants the pharmacist expanded clinical privileges—such as the ability to initiate, modify, or discontinue medication therapy and order lab tests—that go beyond standard dispensing roles
Yes, physicians in India can collaborate with other healthcare professionals, but there is an important distinction:
Is there a formal “Collaborative Practice Agreement (CPA)” system in India?
Not in the same statutory sense as in the United States. I could not find an Indian national framework that gives pharmacists independent prescribing or medication-adjustment authority through a formal physician–pharmacist Collaborative Practice Agreement (CPA).
India's regulatory framework instead keeps prescribing primarily with the Registered Medical Practitioner (RMP). The Pharmacy Council of India states that a registered pharmacist must dispense medicines as prescribed by the RMP and must not substitute the prescription.
The NMC framework also requires medical practice to be performed by persons registered in the State/National Register.
But physician–pharmacist collaboration does exist
The Pharmacy Practice Regulations, 2015 explicitly recognize clinical pharmacists working collaboratively with physicians and other healthcare professionals. They describe clinical pharmacists as providing patient care that optimizes medication use and as often collaborating with physicians.
So there is a distinction:
| Activity | India |
|---|---|
| Physician + pharmacist working as a clinical team | ✅ Yes |
| Pharmacist providing medication information/recommendations | ✅ Yes |
| Pharmacist identifying drug interactions/adverse effects | ✅ Yes |
| Pharmacist discussing therapy with physician | ✅ Yes |
| Pharmacist independently prescribing prescription medicines | ❌ Generally no |
| Pharmacist independently changing physician's prescription | ❌ No |
| U.S.-style CPA giving pharmacist delegated prescribing authority | ❌ No general national framework |
What this means for your pharmacy automation/clinical-pharmacy project
If you're considering a physician–pharmacist collaborative model in India, you could potentially create an institutional “Physician–Clinical Pharmacist Collaborative Medication Management Protocol” within a hospital/healthcare organization.
For example:
Physician
→ diagnoses and establishes treatment
→ authorizes the medication-management protocol
Clinical pharmacist
→ reviews medication
→ checks interactions, duplication, dose, adherence, etc.
→ recommends changes to physician
→ documents intervention
Physician → approves/changes the prescription
This would be quite different from a U.S.-style CPA where state law may authorize the pharmacist to initiate, modify, or discontinue medications. For comparison, the American College of Clinical Pharmacy describes CPAs specifically as agreements supporting pharmacists' authority to initiate, modify, monitor and/or discontinue medications.
Source: Chat GPT
Digital Prescriptions are the solution
Yes—but there is an important distinction between SPUD and SPace.
SPUD (SP Unit Dispenser)
SPUD is primarily designed for unit-of-use medications, meaning the medication remains in its original manufacturer package. It automatically retrieves the correct packaged product and presents it to the pharmacist for barcode verification.
So, if by “strip” you mean a manufacturer’s blister strip/foil strip containing tablets or capsules, SPUD can handle it when that strip is treated as the unit-of-use package and is compatible with the configured product/conveyor.
SPace
Yes, SPace is more versatile. It is designed to dispense:
- Tablets
- Capsules
- Unit-of-use medications, including packaged medications.
The important point is that SPace can dispense bulk tablets/capsules into a prescription vial as well as unit-of-use products.
| Medication form | SPUD | SPace |
|---|---|---|
| Loose tablets | ❌ Not its primary function | ✅ |
| Loose capsules | ❌ Not its primary function | ✅ |
| Tablet blister/strip | ✅ If configured as unit-of-use package | ✅ |
| Capsule blister/strip | ✅ If configured as unit-of-use package | ✅ |
| Original manufacturer pack | ✅ | ✅ |
| Dispensing into vial | ❌ Primarily retrieves package | ✅ |
For an Indian retail pharmacy, this distinction is particularly important because many medicines are supplied as 10/15/20-tablet blister strips. If your objective is to automate strip dispensing without opening the strip, SPUD/SPace configuration needs to be discussed with ScriptPro for the specific strip dimensions, barcode and packaging.
If you tell me which Indian medicines/brands you want to dispense (e.g., 10-tablet strips, 15-tablet strips, capsules), I can investigate whether SPUD or SPace can actually handle those Indian blister-strip formats and how the machine loads them.
Modern times require Modern Solutions
I searched specifically for 2026 pricing for ScriptPro SP 100 and SP 200, including government procurement records and current ScriptPro documentation.
What I found
ScriptPro does not publish an India commercial price/list price for the SP 100 or SP 200. The machines are sold through quotation-based contracts. However, there are useful U.S. government contract prices that give us a realistic benchmark.
| Machine | Published benchmark purchase price | Approx. INR* | Installation benchmark | Approx. INR* |
|---|---|---|---|---|
| SP 100 – Open Control Center | US$140,894 | ₹1.25 crore | US$20,077 | ₹17.8 lakh |
| SP 100 – 6-slot CCC | US$153,900 | ₹1.36 crore | US$21,539 | ₹19.1 lakh |
| SP 100 – 12-slot CCC | US$172,265 | ₹1.52 crore | US$23,366 | ₹20.7 lakh |
| SP 200 configurations | ~US$178,319–199,767 | ~₹1.58–1.77 crore | ~US$23,700+ | ~₹21 lakh+ |
*INR figures are approximate conversions for comparison and do not include Indian customs duty, IGST/GST, freight, insurance, Indian installation/travel costs, site preparation, software/interfaces, or other accessories. The published U.S. figures are government/FSS schedule benchmarks, not an Indian quotation.
Important finding for India
For an Indian pharmacy/hospital, I would not simply convert the U.S. price and assume that is the landed price.
A realistic India installed project budget could be considerably higher once you add:
- International freight and insurance
- Customs duty
- IGST
- Indian electrical/site modifications
- Installation and commissioning
- SP Central pharmacy software/interface
- Vial dispensers and dispensing cells
- Barcode/inspection camera
- Training
- AMC/customer support
- Travel and accommodation for ScriptPro engineers
- Integration with the pharmacy's existing PMS
The SP 100 holds 100 dispensing cells, while SP 200 holds 200 cells, and both can process up to 150 vials/hour according to ScriptPro's current specifications.
One very useful real-world price
I also found a 2023 U.S. Indian Health Service purchase order for an SP 200/CCC for US$141,043.20. This is an actual government purchase order rather than an estimated market price, although it should not be treated as today's Indian commercial price.
There is also a used SP 200/CCC currently advertised at US$39,500, showing how dramatically the price can differ in the secondary market.
My estimate for India
Based on these benchmarks, I would use approximately:
SP 100: ₹1.5–2.0 crore+ installed in India
SP 200: ₹1.8–2.5 crore+ installed in India
These are budgetary estimates, not a confirmed ScriptPro India quotation. The final price could be outside these ranges depending on configuration and import/tax structure.
If you are considering this for an Indian pharmacy, I can next investigate whether ScriptPro has an India distributor/authorized representative and whether SP 100/SP 200 machines have actually been installed in India, including hospitals/pharmacy names and locations.
Yes—but there is an important distinction between SPUD and SPace.
SPUD (SP Unit Dispenser)
SPUD is primarily designed for unit-of-use medications, meaning the medication remains in its original manufacturer package. It automatically retrieves the correct packaged product and presents it to the pharmacist for barcode verification.
So, if by “strip” you mean a manufacturer’s blister strip/foil strip containing tablets or capsules, SPUD can handle it when that strip is treated as the unit-of-use package and is compatible with the configured product/conveyor.
SPace
Yes, SPace is more versatile. It is designed to dispense:
- Tablets
- Capsules
- Unit-of-use medications, including packaged medications.
The important point is that SPace can dispense bulk tablets/capsules into a prescription vial as well as unit-of-use products.
| Medication form | SPUD | SPace |
|---|---|---|
| Loose tablets | ❌ Not its primary function | ✅ |
| Loose capsules | ❌ Not its primary function | ✅ |
| Tablet blister/strip | ✅ If configured as unit-of-use package | ✅ |
| Capsule blister/strip | ✅ If configured as unit-of-use package | ✅ |
| Original manufacturer pack | ✅ | ✅ |
| Dispensing into vial | ❌ Primarily retrieves package | ✅ |
For an Indian retail pharmacy, this distinction is particularly important because many medicines are supplied as 10/15/20-tablet blister strips. If your objective is to automate strip dispensing without opening the strip, SPUD/SPace configuration needs to be discussed with ScriptPro for the specific strip dimensions, barcode and packaging.
If you tell me which Indian medicines/brands you want to dispense (e.g., 10-tablet strips, 15-tablet strips, capsules), I can investigate whether SPUD or SPace can actually handle those Indian blister-strip formats and how the machine loads them.
For modern times an ideal prescription should be a computerized printed form prescription with barcode or QR code
I searched specifically for 2026 pricing for ScriptPro SP 100 and SP 200, including government procurement records and current ScriptPro documentation.
What I found
ScriptPro does not publish an India commercial price/list price for the SP 100 or SP 200. The machines are sold through quotation-based contracts. However, there are useful U.S. government contract prices that give us a realistic benchmark.
| Machine | Published benchmark purchase price | Approx. INR* | Installation benchmark | Approx. INR* |
|---|---|---|---|---|
| SP 100 – Open Control Center | US$140,894 | ₹1.25 crore | US$20,077 | ₹17.8 lakh |
| SP 100 – 6-slot CCC | US$153,900 | ₹1.36 crore | US$21,539 | ₹19.1 lakh |
| SP 100 – 12-slot CCC | US$172,265 | ₹1.52 crore | US$23,366 | ₹20.7 lakh |
| SP 200 configurations | ~US$178,319–199,767 | ~₹1.58–1.77 crore | ~US$23,700+ | ~₹21 lakh+ |
*INR figures are approximate conversions for comparison and do not include Indian customs duty, IGST/GST, freight, insurance, Indian installation/travel costs, site preparation, software/interfaces, or other accessories. The published U.S. figures are government/FSS schedule benchmarks, not an Indian quotation.
Important finding for India
For an Indian pharmacy/hospital, I would not simply convert the U.S. price and assume that is the landed price.
A realistic India installed project budget could be considerably higher once you add:
- International freight and insurance
- Customs duty
- IGST
- Indian electrical/site modifications
- Installation and commissioning
- SP Central pharmacy software/interface
- Vial dispensers and dispensing cells
- Barcode/inspection camera
- Training
- AMC/customer support
- Travel and accommodation for ScriptPro engineers
- Integration with the pharmacy's existing PMS
The SP 100 holds 100 dispensing cells, while SP 200 holds 200 cells, and both can process up to 150 vials/hour according to ScriptPro's current specifications.
One very useful real-world price
I also found a 2023 U.S. Indian Health Service purchase order for an SP 200/CCC for US$141,043.20. This is an actual government purchase order rather than an estimated market price, although it should not be treated as today's Indian commercial price.
There is also a used SP 200/CCC currently advertised at US$39,500, showing how dramatically the price can differ in the secondary market.
My estimate for India
Based on these benchmarks, I would use approximately:
SP 100: ₹1.5–2.0 crore+ installed in India
SP 200: ₹1.8–2.5 crore+ installed in India
These are budgetary estimates, not a confirmed ScriptPro India quotation. The final price could be outside these ranges depending on configuration and import/tax structure.
If you are considering this for an Indian pharmacy, I can next investigate whether ScriptPro has an India distributor/authorized representative and whether SP 100/SP 200 machines have actually been installed in India, including hospitals/pharmacy names and locations.
Yes—but there is an important distinction between SPUD and SPace.
SPUD (SP Unit Dispenser)
SPUD is primarily designed for unit-of-use medications, meaning the medication remains in its original manufacturer package. It automatically retrieves the correct packaged product and presents it to the pharmacist for barcode verification.
So, if by “strip” you mean a manufacturer’s blister strip/foil strip containing tablets or capsules, SPUD can handle it when that strip is treated as the unit-of-use package and is compatible with the configured product/conveyor.
SPace
Yes, SPace is more versatile. It is designed to dispense:
- Tablets
- Capsules
- Unit-of-use medications, including packaged medications.
The important point is that SPace can dispense bulk tablets/capsules into a prescription vial as well as unit-of-use products.
| Medication form | SPUD | SPace |
|---|---|---|
| Loose tablets | ❌ Not its primary function | ✅ |
| Loose capsules | ❌ Not its primary function | ✅ |
| Tablet blister/strip | ✅ If configured as unit-of-use package | ✅ |
| Capsule blister/strip | ✅ If configured as unit-of-use package | ✅ |
| Original manufacturer pack | ✅ | ✅ |
| Dispensing into vial | ❌ Primarily retrieves package | ✅ |
For an Indian retail pharmacy, this distinction is particularly important because many medicines are supplied as 10/15/20-tablet blister strips. If your objective is to automate strip dispensing without opening the strip, SPUD/SPace configuration needs to be discussed with ScriptPro for the specific strip dimensions, barcode and packaging.
If you tell me which Indian medicines/brands you want to dispense (e.g., 10-tablet strips, 15-tablet strips, capsules), I can investigate whether SPUD or SPace can actually handle those Indian blister-strip formats and how the machine loads them.
Thursday, 27 August 2026
A day in the life of Medical Sales Representative or Pharmacy Sales Representative
Thursday, 13 August 2026
A new development may occur or may not
I checked the claim in the newspaper image against the official Pharmacy Council of India (PCI) sources and recent web results.
Verdict: ❌ The main claim is not currently authentic as stated
The article claims that:
Registered pharmacists will be allowed to open clinics, provide primary treatment and prescribe medicines after completing a 3-month MBBS-related course/training.
I could not find an official Gazette notification, PCI regulation, Ministry of Health notification, or NMC notification establishing such a new legal right as of 13 August 2026.
More importantly, the official PCI material currently available does not support this interpretation.
- PCI's official regulations page lists the Pharmacy Practice Regulations, 2015, along with amendments in 2021 and 2025. The 2025 amendment is about adding M.Pharm (Pharmacy Practice) to the clinical-pharmacist qualification; it does not authorize pharmacists to independently diagnose patients or run medical clinics.
- PCI's own FAQ states that under Regulation 4.3, a registered pharmacist is required to dispense medicines against prescriptions of a Registered Medical Practitioner.
- PCI's FAQ also lists the approved pharmacy qualifications for pharmacist registration. It does not list a 3-month MBBS/clinical course that grants independent medical-practice rights.
- The official 2025 Gazette amendment I found contains no provision giving pharmacists authority to open clinics or prescribe medicines independently.
What appears to have happened
The newspaper article appears to be reporting a proposal/claim, rather than an implemented legal rule. There are several social-media posts circulating the same headline, but at least one recent professional discussion explicitly notes that no official policy/gazette confirming this change has been issued.
Also, the wording in the article itself is a red flag: it says “PCI के प्रस्ताव पर केंद्र की मुहर” but does not provide a Gazette notification number, notification date, regulation number, or official Ministry/PCI order establishing the alleged new scope of practice.
Important distinction
A pharmacist can perform professional pharmacy functions within the legal scope of pharmacy practice. That is very different from being legally authorized to:
- independently diagnose diseases,
- establish a medical clinic as a medical practitioner,
- prescribe prescription-only medicines independently, or
- practice medicine after only 3 months of training.
A 3-month training course does not make a pharmacist an MBBS doctor.
So, if you are asking whether a B.Pharm/D.Pharm pharmacist can now legally open a clinic and prescribe medicines after a 3-month course, my answer is:
❌ No — do not rely on this newspaper article as evidence of such a legal right.


